Oncology

Does your drug reach the tumor cells?

In heterogeneous tumor micro-environment, the different levels of vascularization, cellular densities,  the investigation of the drug penetration in the tumor tissue as well as the exposure of drugs to tumors cells are key parameters for the evaluation of a cancer treatment. From Drug discovery to clinical stage,  These data will help to anticipate failure, to measure the potential of drug efficacy and optimize the dosing for future clinical trials.  We are able to quantify and localize drugs and biomarkers in the targeted cells (tumor cells, immune cells) with the combination of different innovative technologies (spatial bioanalysis, molecular imaging, Multimaging™ software, spatially resolved gene expression, high multiplexing histology). These unique innovations help you to define the potential applications of your treatment to different tumors types and cancers and reduce the risk of failure.

Moreover, we can measure the impact of the drug to tumor cells and companion biomarkers to finally quantify the pharmacokinetics and pharmacodynamics at the site of action of the drugs for a precise measure of drug efficacy. This platform has been integrated into innovative in-tissue PK/PD study and Digital Pathology Services to offer a better predictive tool. 

Get access to the Biomarker list and build your panel Here

Our Experiences?

Since ImaBiotech have been founded, we have measured and quantified around 200 drug distribution in tumors. In 90% of the case, the concentration of the drug, the penetration and the rate of exposure to tumor cells shown interesting features and the necessity to adapt the concentration and optimize conditions (formulations). We have experienced in large number of models (Orthotopic models and Xenograft tissues) in many applications (Breast Cancer, Colon Cancer, Brain Cancer, Prostate Cancer) from large to very small tissues (Core needle Biopsy) that allows ImaBiotech to perform preclinical, translational and clinical studies.